[1]房晨鹂?铁馨 刘元汉.妊娠合并肺动脉高压的发病机制及性激素的作用[J].心血管病学进展,2021,(7):625-627,641.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.012]
 FANG Chenli,TIE Xin,LIU Yuanhan,et al.The Pathogenesis of Pregnancy with Pulmonary Hypertension and the Role of Sex Hormones[J].Advances in Cardiovascular Diseases,2021,(7):625-627,641.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.012]
点击复制

妊娠合并肺动脉高压的发病机制及性激素的作用()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年7期
页码:
625-627,641
栏目:
出版日期:
2021-07-25

文章信息/Info

Title:
The Pathogenesis of Pregnancy with Pulmonary Hypertension and the Role of Sex Hormones
作者:
房晨鹂1?铁馨2 刘元汉 3
(1.成都市第三人民医院 心内科,四川 成都 610031;2.重庆医科大学,重庆 400016;3.金堂县妇幼保健院内科,四川 成都 610400)
Author(s):
FANG Chenli1TIE Xin2 LIU Yuanhan3
Department of Cardiology,The Third People’s Hospital of Chengdu,Chengdu 610031,China; 2. Chongqing Medical University,Chongqing 400016, China Department of Internal medicine,Jintang County Maternal and Child Health Hospital,Chengdu 610400,China)
关键词:
肺动脉高压妊娠性激素
Keywords:
Pulmonary hypertension Pregnancy Sex hormone
DOI:
10.16806/j.cnki.issn.1004-3934.2021.07.012
摘要:
肺动脉高压是一种发病机制多样的致死性疾病。它会引起严重的血流动力学紊乱、严重的肺血管重塑、增加肺血管阻力、右心衰竭,最终导致死亡。女性的发病率远高于男性。即使在应用现代先进的靶向药物治疗后死亡率明显下降,但由于仍存在让人难以接受的极高的产妇和胎儿死亡率,指南中禁止肺动脉高压患者怀孕。本文旨在探讨妊娠合并肺动脉高压患者的发病机制及性激素在其中的作用。
Abstract:
Pulmonary hypertension is a kind of fatal disease with various pathogenesis. It is characterized by elevated pulmonary artery pressure and pulmonary vascular remodeling and that frequently lead to right ventricular failure and death. The incidence of women is much higher than that of men. Even after the wide use of pulmonary vascular-targeted medications,pregnancy in pulmonary hypertension is still contraindicated in practice guidelines due to high maternal and fetal morbidity and mortality.The purpose of this paper is to investigate the pathogenesis and role of sex hormones in patients with pregnancy complicated with pulmonary hypertension

参考文献/References:

[1].Tuder RM,Archer SL,Dorfmüller P,et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension[J]. J Am Coll Cardiol,2013,62(25 Suppl):D4-D12.
[2].Condon DF,Nickel NP,Anderson R,et al. The 6th World Symposium on Pulmonary Hypertension:what’s old is new[J].?F1000Res,2019,?8:F1000 Faculty Rev-888.
[3].Hemnes AR,Kiely DG,Cockrill BA,et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute[J]. Pulm Circ,2015,5(3):435-465.
[4].Simonneau G,Gatzoulis MA,Adatia I,et al. Updated clinical classification of pulmonary hypertension[J]. J Am Coll Cardil,2013,62(25 suppl.):D34-D41.
[5].Sliwa K,van Hagen IM,Budts W,et al. Pulmonary hypertension and pregnancy outcomes:data from the Registry of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology[J]. Eur J Heart Fail,2016,18(9):1119-1128.
[6].Assad TR,Maron BA,Robbins IM,et al. Prognostic effect and longitudinal hemodynamic assessment of borderline pulmonary hypertension[J]. JAMA Cardiol,2017,2(12):1361-1368.
[7].Maron BA,Hess E,Maddox TM,et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort:insights from the veterans affairs clinical assessment,reporting,and tracking program[J]. Circulation,2016,133(13):1240-1248.
[8].Douschan P,Kovacs G,Avian A,et al.Mild elevation of pulmonary arterial pressure as a predictor of mortality[J]. Am J Respir Crit Care Med,2018,197(4):509-516.
[9].中华医学会呼吸病学分会肺栓塞与肺血管病组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组,等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志,2021,101(1):11-51.
[10].Prins KW,Rose L,Archer SL,et al. Clinical determinants and prognostic implications of right ventricular dysfunction in pulmonary hypertension caused by chronic lung disease[J]. J Am Heart Assoc,2019,8(2):e011464.
[11].Lahm T,Crisostomo PR,Markel TA,et al. Selective estrogen receptor-α and estrogen receptor-β agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism[J]. Am J Physiol Regul Integr Comp Physiol,2008,295(5):R1486-R1493.
[12].Jones RD,English KM,Pugh PJ,et al. Pulmonary vasodilatory action of testosterone:evidence of a calcium antagonistic action[J]. J Cardiovasc Pharmacol,2002,39(6):814-823.
[13].Tofovic SP. Estrogens and development of pulmonary hypertension:interaction of estradiol metabolism and pulmonary vascular disease[J]. J Cardiovasc Pharmacol,2010,56(6):696-708.
[14].Kawut SM,Al-Naamani N,Agerstrand C,et al. Determinants of right ventricular ejection fraction in pulmonary arterial hypertension[J]. Chest,2009,135(3):752-759.
[15].Dempsie Y,MacRitchie NA,White K,et al. Dexfenflfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension[J]. Cardiovasc Res,2013,99(1):24-34.
[16].White K,Loughlin L,Maqbool Z,et al. Serotonin transporter,sex,and hypoxia:microarray analysis in the pulmonary arteries of mice identififies genes with relevance to human PAH[J]. Physiol Genomics,2011,43(8):417-437.
[17].Oka M,Karoor V,Homma N,et al. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension[J]. Cardiovasc Res,2007,74(3):377-387.
[18].Xu DQ,Luo Y,Liu Y,et al. Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats[J]. Respir Res,2010,11(1):182.
[19].H?nicke U,Albrecht S,Schr?tter H,et al. Prolactin and its 16-kDa N-terminal fragment:are higher in patients with precapillary pulmonary hypertension than in a healthy control group[J]. Tex Heart Inst J,2012,39(1):44-50.
[20].Hernández-Díaz S,van Marter LJ,Werler MM,et al. Risk factors for persistent pulmonary hypertension of the new-born[J]. Pediatrics,2007,120(2):e272-e282.
[21].Lahm T,Patel KM,Crisostomo PR,et al. Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction:the effects of sex and menstrual cycle[J]. Am J Physiol Endocrinol Metab,2007,293(3):E865-E871.
[22].Murphy E. Estrogen signaling and cardiovascular disease[J]. Circ Res,2011,109(6):687-696.
[23].Ventetuolo CE,Ouyang P,Bluemke DA,et al. Sex hormones are associated with right ventricular structure and function:the MESA-right ventricle study[J]. Am J Respir Crit Care Med,2011,183(5):659-667.
[24].Umar S,Iorga A,Matori H,et al. Estrogen rescues preexisting severe pulmonary hypertension in rats[J]. Am J Respir Crit Care Med,2011,184(6):715-723.
[25].Lahm T,Albrecht M,Fisher AJ,et al. 17β-estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects[J]. Am J Respir Crit Care Med,2012,185(9):965-980.
[26].Cheng TC,Philip JL,Tabima D,et al. Estrogen receptor alpha prevents right ventricular diastolic dysfunction and fibrosis in female rats[J]. Am J Physiol Heart Circ Physiol,2020,319(6):H1459-H1473.
[27].Alzoubi A,Toba M,Abe K,et al. Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension[J]. Am J Physiol Heart Circ Physiol,2013,304(12):H1708-H1718.
[28].Dumas-de La Roque E,Bellance N,et al. Dehydroepiandrosterone reverses chronic hypoxia/reoxygenation-induced right ventricular dysfunction in rats[J]. Eur Respir J,2012,40(6):1420-1429.
[29].Hemnes AR,Maynard KB,Champion HC,et al. Testosterone negatively regulates right ventricular load stress responses in mice[J]. Pulm Circ,2012,2(3):352-358.
[30].Hester J,Ventetuolo C,Lahm T. Sex,Gender,and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure[J]. Compr Physiol,2019,10(1):125-170.

相似文献/References:

[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
 MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(7):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
 ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(7):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
 WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(7):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
 WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(7):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
 DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(7):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[6]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
 ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(7):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[7]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
 ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(7):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[8]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
 HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(7):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[9]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
 LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(7):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[10]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
 Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(7):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]

更新日期/Last Update: 2021-09-10